APELLIS PHARMACEUTICALS INC's ticker is and the CUSIP is 03753UAB2. A total of 23 filers reported holding APELLIS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,591,416 | -48.4% | 1,285,000 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $3,084,719 | +29.1% | 1,285,000 | 0.0% | 0.00% | – |
| Q1 2023 | $2,389,689 | -37.5% | 1,285,000 | -48.1% | 0.00% | -100.0% |
| Q4 2022 | $3,824,630 | -48.9% | 2,476,000 | -35.7% | 0.00% | -50.0% |
| Q3 2022 | $7,491,000 | -13.3% | 3,853,000 | -33.4% | 0.00% | 0.0% |
| Q2 2022 | $8,639,000 | -9.5% | 5,788,000 | -3.9% | 0.00% | 0.0% |
| Q1 2022 | $9,544,000 | +8.4% | 6,025,000 | +3.4% | 0.00% | +100.0% |
| Q4 2021 | $8,807,000 | +43.2% | 5,825,000 | +16.2% | 0.00% | 0.0% |
| Q3 2021 | $6,151,000 | -25.7% | 5,015,000 | +11.7% | 0.00% | 0.0% |
| Q2 2021 | $8,279,000 | +270.9% | 4,490,000 | +182.4% | 0.00% | – |
| Q1 2021 | $2,232,000 | -19.4% | 1,590,000 | -3.6% | 0.00% | -100.0% |
| Q4 2020 | $2,769,000 | +57.0% | 1,650,000 | 0.0% | 0.00% | – |
| Q3 2020 | $1,764,000 | – | 1,650,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 41,825,000 | $77,769,000 | 1.38% |
| STEELHEAD PARTNERS LLC | 8,474,000 | $15,791,000 | 1.04% |
| DeepCurrents Investment Group LLC | 12,750,000 | $23,782,000 | 0.71% |
| WOLVERINE ASSET MANAGEMENT LLC | 42,855,000 | $79,763,000 | 0.61% |
| SSI INVESTMENT MANAGEMENT LLC | 4,418,000 | $8,147,000 | 0.53% |
| LMR Partners LLP | 13,925,000 | $26,144,000 | 0.40% |
| MACKAY SHIELDS LLC | 19,851,000 | $36,702,000 | 0.34% |
| CSS LLC/IL | 2,500,000 | $4,653,000 | 0.19% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 10,500,000 | $19,571,000,000 | 0.18% |
| PALISADE CAPITAL MANAGEMENT, LP | 3,306,000 | $6,173,000 | 0.14% |